Teva announced the launch of Topotecan Injection, the generic version of GlaxoSmithKline’s Hycamtin Injection. Topotecan is indicated for the treatment of metastatic carcinoma of the ovary after failure of initial or subsequent chemotherapy, Stage IV-B, recurrent or persistent carcinoma of the cervix in combination with cisplatin, and small cell lung cancer sensitive disease after failure of 1st line chemotherapy.
Topotecan is a topoisomerase inhibitor that binds to the topoisomerase I-DNA complex and prevents religation of single strand DNA breaks. The cytotoxicity of topotecan is thought to be due to double strand DNA damage produced during DNA synthesis, when replication enzymes interact with the ternary complex formed by topotecan, topoisomerase I, and DNA.
Topotecan Injection is available as a 1mg/mL strength in 4mL single-dose vials.
For more information call (888) 838-2872 or visit TevaGenerics.com.